Overview
- Researchers reported in Med that 27 healthy men in Japan received a single intrarectal dose of non-oxygenated perfluorodecalin, up to 1,500 ml, retained for 60 minutes.
- Twenty participants completed the full hour, with only mild abdominal bloating and discomfort at the highest volume, no serious adverse events, and normal laboratory results.
- The team, led by Takanori Takebe of Cincinnati Children’s and the University of Osaka, emphasized that the data address safety only and not oxygen delivery effectiveness.
- Next studies will use fully oxygenated perfluorodecalin to measure blood-oxygen increases, guided by predictions from large-animal models.
- The work, which follows prior porcine research and 2024 IgNobel recognition, is being advanced by EVA Therapeutics, with future trial timing dependent on fundraising and a potential role as an adjunct for severe respiratory compromise if efficacy is shown.